EAM Investors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

EAM Investors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-25,587	Closed	-$1.99M	–	436
2020 Q3	$1.99M	Sell	25,587 -9,724	-28%	-$669K	0.47%	58
2020 Q2	$1.96M	Buy	+35,311	New	+$1.51M	0.43%	88
2019 Q3	–	Sell	-63,088	Closed	-$1.52M	–	334
2019 Q2	$1.52M	Sell	63,088 -5,802	-8%	-$147K	0.37%	122
2019 Q1	$1.82M	Sell	68,890 -20,753	-23%	-$492K	0.45%	77
2018 Q4	$1.75M	Buy	+89,643	New	+$1.76M	0.48%	74
2014 Q3	–	Sell	-163,324	Closed	-$2.58M	–	385
2014 Q2	$2.58M	Sell	163,324 -138,410	-46%	-$1.98M	0.49%	35
2014 Q1	$4.56M	Sell	301,734 -135,850	-31%	-$1.53M	0.82%	5
2013 Q4	$3.33M	Buy	+437,584	New	+$2.36M	0.6%	22

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's HZNP Position: Q4 2020 in Review

EAM Investors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 25,587 shares — an estimated $1.99M sold.

EAM Investors first reported a position in HZNP in Q4 2013 and held it in 8 quarters. The position peaked at $4.56M in Q1 2014. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

EAM Investors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
EAM Investors sold 25,587 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $1.99M.
EAM Investors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 8 quarters.
EAM Investors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.56M in Q1 2014.
497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on EAM Investors's 13F filing for Q4 2020, filed 11 Feb 2021.